Floatz logo

Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide

Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.antibody_drug_conjugatePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
59/ 100

Competitive context

848 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Vandana Abramson
Phase 2BBB
Pertuzumab
SWOG Cancer Research Network
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Goserelin
TerSera Therapeutics LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide is also rated in:

non-small cell lung carcinomaActive
B
Indicative · Phase 3
63 / 100
View asset →
urinary system neoplasmActive
B
Indicative · Phase 2
60 / 100
View asset →
small cell lung carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →